Navigation Links
Genentech and Novartis Remain Image Leaders in Oncology and Hematology
Date:6/2/2011

LIVONIA, Mich., June 2, 2011 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2011 MSImage study. The study evaluated more than 30 sales force, corporate equity and R&D attributes to determine which measures drive a company's image and performance in this rapidly growing marketplace.

Amgen, Sanofi-aventis and Eli Lilly/ImClone round out the top five among oncologists, and Celgene, Millennium: The Takeda Oncology Company and Amgen round out the top five for hematologists.Rank

Oncologists

Hematologists1

Genentech

Genentech2

Novartis

Novartis3

Amgen

Celgene4

Sanofi-aventis

Millennium5

Eli Lilly/ImClone

AmgenWhile Genentech maintains a slim lead across office-based and hospital-based oncologists and hematologists, Novartis remains the only other company tied with Genentech for top-tier status.  And, although Genentech slightly extended their lead across several key measures, Novartis is now ranked first by hospital oncologists in the Sales Force dimension and closed the gap on Genentech in the Product/R&D dimension.  

"Last year, Novartis joined Genentech as a top-tier company among office-based oncologists, but now the improvement is mixed. There are specific areas that Novartis needs to improve on if it hopes to claim the top spot from Genentech," said Brock Walter, vice president, Specialty Pharmaceuticals division, Market Strategies International.

Study results indicate that top performers engage in behaviors that are most important to physicians. Specifically, there is a strong correlation between a highly favorable image and behaviors such as a physician's likelihood to:

  • Recommend products to colleagues
  • Make additional time for sales reps and MSLs
  • Try new products
  • Carefully read literature from the company
  • Enroll patients in company clinical trials

  • Amgen had its best year across all oncology stakeholders and jumped from fifth to third place in overall image among office-based and hospital-based oncologists. It also saw large gains in the Sales Force dimension, highlighting the impact a comprehensive approach to an office can make.

    Among hematologists, it's important to note that Celgene and Millennium: The Takeda Oncology Company captured two of the top five spots, challenging the perception that small companies cannot be image leaders.

    "Companies are realizing that image and reputation go beyond having the most products; it's about having knowledgeable, responsive sales reps that provide the objective data oncologists want and having the support programs and information nurses and practice managers need," said Dr. Shawn Wade, vice president and head of Specialty Pharmaceuticals at Market Strategies.

    For more information on this and other syndicated studies on European Oncologists/ Hematologists and top performers at ASCO, contact Brock Walter at 909.267.5443 or brock.walter@marketstrategies.com.

    About the StudyMarket Strategies' 2011 MSImage Oncology and Hematology Stakeholder Study was fielded via the Internet in February and March among 465 physicians, 100 oncology practice managers and 100 oncology nurses. To qualify, physicians and nurses were required to have a minimum number of oncology patients, spend at least 50 percent of their time in patient care and have exposure to sales representatives. To qualify as a practice manager, respondents were required to work in a practice with at least three oncologists and be responsible for billing and reimbursement. Respondents were recruited from a national e-research panel. Due to its opt-in nature, this online panel (like most others) does not yield a random probability sample of the target population.

    About Market Strategies InternationalMarket Strategies International is a market research consultancy with deep expertise in the communication, energy, financial services, healthcare and technology industries. We design and implement the most intelligent research and deliver meaningful results that help companies make business decisions with complete and total confidence. Founded in 1989, Market Strategies is the 17th largest research firm in the US according to "Honomichl Top 50," published in the June 2010 issue of Marketing News.


    '/>"/>

    SOURCE Market Strategies International
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
    2. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
    3. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
    4. Roche Completes Tender Offer for Genentech
    5. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
    6. MRC Technology Enters Into an Exclusive License Agreement With Genentech
    7. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
    8. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
    9. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
    10. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
    11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
    (Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
    (Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
    Breaking Biology Technology:
    (Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
    (Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
    (Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
    Breaking Biology News(10 mins):